NOBORI Biolimus-Eluting versus XIENCE/PROMUS Everolimus-eluting Stent Trial

NOBORI Biolimus-Eluting versus XIENCE/PROMUS Everolimus-eluting Stent Trial - NEXT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004661

Enrollment

3200

Registered

2010-12-03

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Percutaneous coronary intervention using biolimus-eluting stent. Percutaneous coronary intervention using everolimus-eluting stent.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing percutaneous coronary intervention using drug eluting stent.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Taget lesion revascularization within one year after percutaneous coronary intervention. Incidence of cardiac death and myocardial infarction within 3 years after percutaneous coronary intervention.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026